Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN), a clinical-stage oncology company, announce that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion. This equates to approximately $5.7 billion net of acquired cash and represents an approximate premium of 31% to the 60-day and 42% to the 90-day volume-weighted average stock price on March 24, 2026.
Read the full article: Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline with TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) //
Source: https://www.businesswire.com/news/home/20260325654199/en/Merck-to-Acquire-Terns-Pharmaceuticals-Inc.-Expanding-Its-Hematology-Pipeline-With-TERN-701-a-Novel-Candidate-for-Chronic-Myeloid-Leukemia-CML